Pharma has stepped up its efforts around utilizing real-world data for drug approvals, but reproducing randomized controlled trials (RCTs) using real-world evidence (RWE) is challenging and the two are “not in competition” and complementary, a senior Janssen Pharmaceuticals Inc. executive has emphasized.
Addressing the Indegene Digital Summit, Janssen’s Chief Commercial Data Science Officer Troy Sarich indicated that while there’s been increasing use...